GAP President John Dwyer, on behalf of the organization, joined other Alzheimer’s advocates in Washington D.C. for the ‘Rally for Access’ on March 15, 2022.
The ‘Rally for Access’ gathered these organizations to remind the public what is at stake if the Centers for Medicare and Medicaid Services (CMS) National Coverage Determination (NCD) is accepted. Currently, the decision would limit not only Aduhelm, the first Alzheimer’s Disease drug approved in nearly 20 years, but every drug in that class. Every future Alzheimer’s drug would be limited if this decision were to be approved. This wouldn’t only affect those living with AD but those living with Down Syndrome, which is the most common genetic cause of developing Alzheimer’s.
Our friends and partners at the Alliance for Aging Research created a video of key speakers and advocates at the rally. Watch it below.